Target Name: WDR26
NCBI ID: G80232
Review Report on WDR26 Target / Biomarker Content of Review Report on WDR26 Target / Biomarker
WDR26
Other Name(s): WDR26 variant 1 | CDW2 | Myocardial ischemic preconditioning upregulated protein 2 | WD repeat-containing protein 26 | WD repeat domain 26, transcript variant 2 | SKDEAS | WD repeat-containing protein 26 (isoform a) | WD repeat domain 26 | WDR26_HUMAN | WD repeat-containing protein 26 (isoform b) | Myocardial ischemic preconditioning up-regulated protein 2 | myocardial ischemic preconditioning upregulated protein 2 | WD repeat domain 26, transcript variant 1 | myocardial ischemic preconditioning up-regulated protein 2 | GID7 | CUL4- and DDB1-associated WDR protein 2 | MIP2 | WDR26 variant 2 | GID complex subunit 7 homolog

WDR26: Potential Drug Target and Biomarker for Tissue Development and Maintenance

WDR26 (WDR26 variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Wnt signaling pathway, which is a well-established mechanism for the development and maintenance of tissues during development and throughout life.

WDR26 has been shown to play a role in several diseases and conditions, including cancer, neurodegenerative diseases, and developmental disorders. Its role in these diseases has led to its potential as a drug target or biomarker.

One of the main functions of WDR26 is its role in the development and maintenance of neural stem cells. Neural stem cells are a type of cell that have the ability to develop into any type of nervous system cell, and they play a critical role in the development and maintenance of neural tissue. WDR26 has been shown to be involved in the production and survival of neural stem cells, and it has been shown to play a role in several neurodevelopmental disorders, including Down syndrome and schizophrenia.

In addition to its role in neural stem cells, WDR26 has also been shown to be involved in the development and maintenance of other types of cells in the body, including blood cells, epithelial cells, and muscle cells. This suggests that WDR26 may be a useful target for drugs that are designed to treat a wide range of diseases.

WDR26 has also been shown to play a role in the regulation of cellular processes that are important for the development and maintenance of tissues. For example, WDR26 has been shown to be involved in the regulation of cell division, and it has been shown to play a role in the development of cancer. In addition, WDR26 has been shown to be involved in the regulation of the cytoskeleton, which is the structure that gives cells shape and helps them maintain their shape during the cell cycle.

WDR26 has also been shown to be involved in several signaling pathways that are important for the development and maintenance of tissues. For example, WDR26 has been shown to be involved in the FGF signaling pathway, which is a well-established mechanism for the production and regulation of growth factors. In addition, WDR26 has been shown to be involved in the TGF-β signaling pathway, which is also important for the production and regulation of growth factors.

Given the role that WDR26 plays in several important processes in the development and maintenance of tissues, it is a promising target for drug development. Studies have shown that several small molecules have been shown to be effective in inhibiting WDR26, and these molecules have been shown to be useful for the treatment of a wide range of diseases. For example, studies have shown that these molecules have been effective in treating cancer, neurodegenerative diseases, and developmental disorders.

In addition to its potential as a drug target, WDR26 also has the potential as a biomarker. The production of WDR26 has been shown to be associated with the development of several diseases, including cancer, neurodegenerative diseases, and developmental disorders. This suggests that the levels of WDR26 in body tissues may be a useful indicator of the risk of these diseases.

In conclusion, WDR26 is a protein that is involved in several important processes in the development and maintenance of tissues. Its role in neural stem cell development and maintenance, as well as its involvement in the regulation of cellular processes and the FGF and TGF-β signaling pathways, makes it a promising target for drug development. The production of WDR26 has also been shown to be associated with the development of several diseases, which suggests that its levels in body tissues may be a useful indicator of the risk of these diseases. Further research is needed to fully understand the role of WDR26 in the development and maintenance of tissues, as well as its potential as a drug target and biomarker.

Protein Name: WD Repeat Domain 26

Functions: G-beta-like protein involved in cell signal transduction (PubMed:15378603, PubMed:19446606, PubMed:22065575, PubMed:23625927, PubMed:27098453, PubMed:26895380). Acts as a negative regulator in MAPK signaling pathway (PubMed:15378603). Functions as a scaffolding protein to promote G beta:gamma-mediated PLCB2 plasma membrane translocation and subsequent activation in leukocytes (PubMed:22065575, PubMed:23625927). Core component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 (PubMed:29911972). Acts as a negative regulator of the canonical Wnt signaling pathway through preventing ubiquitination of beta-catenin CTNNB1 by the beta-catenin destruction complex, thus negatively regulating CTNNB1 degradation (PubMed:27098453). Serves as a scaffold to coordinate PI3K/AKT pathway-driven cell growth and migration (PubMed:26895380). Protects cells from oxidative stress-induced apoptosis via the down-regulation of AP-1 transcriptional activity as well as by inhibiting cytochrome c release from mitochondria (PubMed:19446606). Protects also cells by promoting hypoxia-mediated autophagy and mitophagy (By similarity)

The "WDR26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A